Abstract: The present disclosure generally relates to compositions and techniques for treatment of dysmenorrhea using intravaginal delivery. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 800,000 cP. The composition may also contain an active ingredient for treatment of dysmenorrhea (e.g., primary dysmenorrhea), e.g., diclofenac, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for making or using such compositions, kits including such compositions, or the like.

Abstract: The present disclosure generally relates to compositions and methods for treating polycystic ovarian syndrome (PCOS) and/or endometriosis. The composition may contain an active ingredient for treatment of PCOS and/or endometriosis, e.g., melatonin, a melatonin receptor agonist, and/or salts thereof. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. In some embodiments, a drug delivery device containing the active agent may be inserted in the vagina. In some embodiments, the drug delivery device is an intravaginal ring.

Abstract: The present disclosure generally relates to compositions and techniques for treatment of female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition such as a cream may be applied to the genital of a subject. The composition may also contain an active ingredient for treatment of FSD and/or FSAD, e.g., sildenafil, and/or pharmaceutically acceptable salts thereof. In addition, certain embodiments as described herein are generally directed to techniques for using such compositions, kits including such compositions, or the like.

Abstract: The present invention is in the field of intravaginal rings, in particular segmented, ethylene-vinyl acetate (EVA) intravaginal rings, and their use treating, ameliorating, or preventing, vasomotor symptoms in perimenopause and/or menopausal women and for treating, ameliorating, or preventing vulvar and vaginal atrophy (VVA).

Abstract: Disclosed herein are segmented EVA Rings that contain progesterone that can be used to prevent preterm birth in subjects with a shortened cervix or to treat luteal phase deficiency or as luteal phase support.

Abstract: Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.

Abstract: The present disclosure generally relates to compositions and techniques for vaginal insertion. In some embodiments, a composition such as a gel may be applied to the vagina of a subject that is relatively viscous, for example, with a viscosity at room temperature of at least 1.5 million cP. The composition may also contain an active ingredient, e.g., dinoprostone, diclofenac, and/or salts thereof. Compositions having such relatively high viscosities may be useful, for example, to prevent the composition from readily exiting the vagina or degrading too quickly. This may, for example, allow the composition to release the active ingredient over a relatively long period of time to the vagina. In some embodiments, such compositions may be prepared by removing air from the composition to increase its viscosity or cause the composition to form a gel, etc.

Abstract: A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin, wherein said composition has a viscosity of at least 1.5 million mPa·s.

Abstract: Disclosed herein are segmented, EVA intravaginal rings that release 17?-estradiol and progesterone with specific pharmacokinetics useful for treating, ameliorating, and preventing symptoms associated with menopause and vulvar and vaginal atrophy.

Abstract: Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases, and treating and/or preventing bacterial infections. The IVR's are resistant to distortion due to absorption of vaginal fluids. This allows the IVRs to perform better over time as compared to other intravaginal rings made with copolymeric silicone.

Abstract: Disclosed herein are segmented EVA Rings that contain progesterone that can be used to prevent preterm birth in subjects with a shortened cervix or to treat luteal phase deficiency or as luteal phase support.

Abstract: The management of backup sets based on user feedback techniques include a method, and a system. In some embodiments of these techniques, the method includes receiving an update to a backup set from a first client device. The method further includes analyzing the update made to the backup set. The method further includes updating a default backup set stored in a storage device based on the update to the backup set. This Abstract is provided for the sole purpose of complying with the Abstract requirement rules. This Abstract is submitted with the explicit understanding that it will not be used to interpret or to limit the scope or the meaning of the claims.

Abstract: The present disclosure describes systems and methods for reliable backup of data, by initially providing transcoded, down-sampled, or low resolution versions of media data files for backup when a network has low bandwidth or intermittent connectivity, and subsequently providing the original or high resolution copy to replace the transcoded version, either on a second, faster or more reliable network, or over time on the first network. Accordingly, even with poor network conditions, data may be backed up quickly in a reduced size in case of damage to or loss of the device, providing a “better low resolution than no resolution” safety margin.

Abstract: The present disclosure describes systems and methods for reliable backup of data, by initially providing transcoded, down-sampled, or low resolution versions of media data files for backup when a network has low bandwidth or intermittent connectivity, and subsequently providing the original or high resolution copy to replace the transcoded version, either on a second, faster or more reliable network, or over time on the first network. Accordingly, even with poor network conditions, data may be backed up quickly in a reduced size in case of damage to or loss of the device, providing a “better low resolution than no resolution” safety margin.

Abstract: The management of backup sets based on user feedback techniques include a method, and a system. In some embodiments of these techniques, the method includes receiving an update to a backup set from a first client device. The method further includes analyzing the update made to the backup set. The method further includes updating a default backup set stored in a storage device based on the update to the backup set. This Abstract is provided for the sole purpose of complying with the Abstract requirement rules. This Abstract is submitted with the explicit understanding that it will not be used to interpret or to limit the scope or the meaning of the claims.

Abstract: A controlled-release drug delivery system advantageously includes an open-ended, inflexible sleeve, at least two controlled-release layers and two open-center caps. Each controlled-release layer abuts a sealing surface that is located within and near each end of the sleeve. The caps seal each controlled-release layer against the abutting sealing surface. One or more dose units of drug are disposed in a region that is formed between the controlled-release layers. The controlled-release layers dissolve, at a predetermined rate, by the action of body fluids that are in contact with those layers through the center of the caps. Release of drug is delayed at least until the controlled-release layers dissolve. The dose unit itself, which is advantageously a core, can be tailored to provide an extended period of drug release. One or more dose units that provide an immediate release component can also be disposed near each end of the sleeve.

Abstract: A method for providing a proactive voice mail service wherein a message is recorded by a voice mail server if the customer's phone line is busy or does not answer and the voice mail server then attempts to deliver the message proactively to the customer. The method avoids loop-back charges which limit the usefulness of present implementations of proactive voice mail and allow for a nation-wide proactive voice mail service utilizing a server with toll-free inbound phone lines.

Abstract: A method for providing a never-busy fax service wherein a customer's fax machine appears to be never busy to a caller. The method avoids loop-back charges which limit the usefulness of present implementations of never-busy fax and allow for a nation-wide never-busy fax service utilizing a server with toll-free inbound phone lines.

Abstract: An electronic musical instrument incorporates one or more pressure sensitive push-button controllers actuable independent of the keys or other note selecting elements of the instrument to vary a corresponding number of musical parameters. The specific controllers provide a sensitive, smooth, repeatable parameter variation in response to both the location and the force of the player's touch.